MSM(Methylsulfonylmethane) is sold as a sulfur source for joints, and the reasoning sounds tidy. Sulfur is in cartilage. MSM is mostly sulfur. Therefore MSM supports cartilage.
Two things are worth checking before accepting that chain. Whether sulfur is actually in short supply, and how much research sits behind the joint claim.
The second question has a surprisingly specific answer.
What MSM is
MSM — methylsulfonylmethane — is a small sulfur-containing compound found naturally in some foods, and also present in the human body. It turns up in plasma and cerebrospinal fluid at low concentrations without anyone taking a supplement[1].
Sulfur makes up about 34% of MSM by weight[3]. Sulfur itself is the fourth most abundant mineral in the body after calcium, phosphorus and potassium, and sits in relatively large amounts in hair, nails, skin and cartilage[3].
There’s also a family relationship worth knowing. MSM and DMSO are related compounds — roughly 15% of orally ingested DMSO is converted into MSM in the body[1].
The sulfur rationale, and where it thins out
Here’s the part I’d accepted without examining.
The proposed mechanism is that MSM supplies bioavailable sulfur, which feeds into the body’s methionine and cysteine pools — the amino acids that carry sulfur into connective tissue and antioxidant systems. An animal study confirmed that sulfur from ingested MSM does get incorporated into these tissues[3].
So the mechanism is real. But notice what it doesn’t establish.
It doesn’t show that sulfur was scarce to begin with. Methionine and cysteine come from dietary protein, which most people in developed countries eat in adequate amounts. A supplement that supplies more of something you already have enough of is a different proposition from one that corrects a shortfall.
“Sulfur source” is accurate as chemistry. As a rationale for supplementation, it quietly assumes a deficiency that hasn’t been demonstrated.
How much research is there
This is where the numbers get concrete, and small.
The most cited trial is a pilot study of 50 people aged 40 to 76 with knee osteoarthritis, given 3 g of MSM twice daily for 12 weeks[1]. Its own abstract opens by noting the paucity of evidence supporting MSM[1].
A more recent Japanese trial enrolled 88 participants with mild knee pain, using 2,000 mg daily for 12 weeks[3].
Then there’s the meta-analysis, and this is the number worth remembering. Researchers searched for randomised trials of MSM and DMSO in osteoarthritis. Seven candidate trials turned up. Three qualified — two on DMSO, one on MSM — with 326 participants in total[2].
Three hundred and twenty-six people. For an ingredient stocked in every pharmacy.
What the pooled analysis found
| Study | Participants | Dose | Duration | Result |
| Pilot RCT | 50 | 6 g/day | 12 weeks | Pain reduced from baseline |
| Japanese RCT | 88 | 2 g/day | 12 weeks | Primary outcome p = 0.046 |
| Meta-analysis | 326 (3 trials) | mixed | mixed | Not statistically or clinically significant |
[Table 1] Evidence base for MSM in knee osteoarthritis · Source: Related trials and meta-analysis[1][2][3]
The pooled result was a pain reduction of 6.34 mm on a visual analogue scale, with a confidence interval running from −0.49 to 13.17[2]. That interval crosses zero, which means no difference remains a possible answer.
The authors’ conclusion was direct: current evidence suggests DMSO and MSM are not clinically effective in reducing osteoarthritis pain[2]. They also flagged significant heterogeneity between trials and inadequate dosing periods[2].
A separate systematic review covering 1950 to 2007 found only six studies meeting inclusion criteria and reached no definitive conclusions, while noting positive trends[4].
A bit more detail — on why p = 0.046 deserves a second look. That value sits just inside the conventional 0.05 threshold, meaning the result would be called non-significant with a slightly different sample or analysis choice. A single trial landing marginally on the favourable side of the line is weaker evidence than the word “significant” tends to convey, particularly when the pooled analysis of the field found nothing.
The dose is larger than people expect
Worth pausing on the pilot trial’s regimen: 6 grams per day, split into two doses[1].
That’s not a capsule with breakfast. Six grams of anything means several large tablets or a measured powder, twice daily, sustained for months. The Japanese trial used a third of that amount and required ten tablets daily[3].
If you’re comparing products, check what the studied doses were against what the label provides. A product supplying a few hundred milligrams is not delivering what the trials tested — and the trials that tested those amounts didn’t produce convincing results anyway.
Where regulators have landed
Approaches differ, as they usually do.
In the United States, MSM is sold as a dietary supplement under structure/function claims, which as we covered previously are not reviewed or approved by the FDA before use. The manufacturer holds the substantiation.
In Korea, the question is whether the ingredient appears among recognised functional ingredients and, if so, with what approved wording. That’s checkable on the official portal at the time of purchase[5], and worth doing rather than assuming.
The gap between “widely sold” and “demonstrated” is the recurring theme here. MSM is not unusual in that respect — but the evidence base is smaller than its shelf presence suggests.
Closing
MSM is generally well tolerated in the trials conducted, and nothing here suggests it’s harmful. The question is narrower: does the joint claim rest on much?
What changed my reading was the total participant count. I’d assumed an ingredient this established had a substantial literature behind it. The pooled analysis in this area covers 326 people across three trials, two of which weren’t even testing MSM.
That’s not evidence of absence. It’s absence of evidence — and those are worth telling apart before spending money on either.
Next in this series: what glucosamine trials found, and why the salt form changed the answer.
At a Glance
- MSM is about 34% sulfur by weight and occurs naturally in the body
- The mechanism — sulfur feeding methionine and cysteine pools — is real, but doesn’t establish that sulfur was lacking; dietary protein supplies it
- The most cited trial enrolled 50 people; a more recent one enrolled 88
- The meta-analysis in this area pooled three trials and 326 participants, only one of which tested MSM
- Pooled pain reduction was not statistically or clinically significant, with a confidence interval crossing zero
- Studied doses reached 6 g/day — considerably more than many products supply
- Check the recognised functional wording in your market rather than assuming
※ This article is for general information and does not replace medical advice, diagnosis or treatment. Persistent joint pain warrants assessment rather than self-management with supplements. If you take medication or have an existing condition, please consult a clinician before starting any supplement.
References
- Kim LS et al., “Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial”, Osteoarthritis and Cartilage, https://pubmed.ncbi.nlm.nih.gov/16309928/
- Brien S et al., “Meta-Analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonylmethane in the Treatment of Osteoarthritis of the Knee”, PMC, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135791/
- “Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial”, PMC, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346176/
- “Methylsulfonylmethane — an overview” (systematic review summary), ScienceDirect Topics, https://www.sciencedirect.com/topics/medicine-and-dentistry/methylsulfonylmethane
- Food Safety Korea (MFDS), recognised functional ingredient lookup, https://www.foodsafetykorea.go.kr/